US-India Trade Pact: $500B Deal Reached as India Shifts from Russian Oil

American farmers and ranchers stand to gain significantly from India eliminating or reducing tariffs on a wide range of U.S. food and agricultural products. Items like dried distillers' grains, red sorghum, tree nuts, fresh and processed fruit, soybean oil, and other products will become more competitive in India's massive market of over 1.4 billion people. India also agrees to address long-standing non-tariff barriers on U.S. agricultural goods, which have historically blocked or slowed exports.

Small businesses that export to India — especially in agriculture, tech, and medical devices — could benefit from reduced tariffs and simplified regulations. However, small businesses that import Indian goods like textiles, leather, footwear, and home décor will face an 18% reciprocal tariff, raising their costs. The net effect depends heavily on whether a business is an importer or exporter.

While this agreement focuses on trade in goods rather than immigration, expanded U.S.-India economic ties in technology — including GPUs, data centers, and joint tech cooperation — could indirectly affect the large population of Indian nationals on H-1B and other work visas. The agreement doesn't directly change visa rules, but a stronger bilateral relationship could influence future discussions about skilled worker mobility.

The agreement's commitment to address digital trade barriers and set rules for digital commerce could eventually affect gig workers who depend on digital platforms. The framework promises "robust, ambitious, and mutually beneficial digital trade rules" as part of the broader trade agreement, but specific impacts on gig workers remain unclear at this stage.

The agreement removes reciprocal tariffs on generic pharmaceuticals from India, and provides for negotiated outcomes on generic drugs and ingredients pending a U.S. investigation. India is the world's largest supplier of generic medications to the U.S., so keeping those imports affordable directly benefits the millions of Americans who rely on low-cost generics to manage chronic conditions like diabetes, heart disease, and high blood pressure.